Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells

Chinese Medical Journal

Volumn 126, Issue 1, 2013, Pages 129-134

  Zhang, Song ^a   Zhang, Qun Cheng ^a   Jiang, Shu Juan ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Caspase 3; Paclitaxel; Survivin; Trichostatin A

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL) [2, 5' BI 1H BENZIMIDAZOL] 2' YL] PHENOL; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SURVIVIN; TRICHOSTATIN A; TUBULIN; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ACETYLATION; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; PACLITAXEL; TUBULIN;

EID: 84874370583     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20120009     Document Type: Article

References (21)

1. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer 2010;126: 743-755.
2. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol 2009; 77: 1328-1336.
3. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129: 219-229.
4. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 2009; 15: 543-552.
5. Zhang S, Zhang Y, Li S, Wang HM, Mu XY, Jiang SJ. Study on the effect of TSA and paclitaxel on the growth and apoptosis in the endometrial carcinoma cell. Chin J Cancer Biother (Chin) 2008;15: 516-521.
6. Yang YN, Wang Y, Wang XG, Jiang SJ. Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells. Chin J Cancer (Chin) 2008; 27: 816-821.
7. Jiang SJ, Zhang S, Mu XY, Li W, Wang Y. Effects of trichostatin A and paclitaxel on apoptosis and microtubule stabilization in endometrial carcinoma cells: an in vitro research. Natl Med J China (Chin) 2008; 88: 2427-2431.
8. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, et al. Histone deacetylase inhibitiors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5: 2767-2776.
9. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Embo J 2003; 22: 1168-1179.
10. Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007; 120: 1469-1479.
11. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
12. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 1998; 396: 580-584.
13. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 2005; 124: 543-549.
14. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66: 4263-4272.
15. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298.
16. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008; 7: 740-748.
17. Glauben R, Sonnenberg E, Zeitz M, Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009; 280: 154-159.
18. Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010; 11: 36-44.
19. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 2010; 5: 196-208.
20. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010; 45: 2095-2116.
21. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009; 3: 235-243.